Amivantamab, lazertinib, and bevacizumab: a chemotherapy-free option for patients with advanced EGFR-mutant NSCLC with acquired resistance to a third-generation EGFR TKI
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Amivantamab, lazertinib, and bevacizumab: a chemotherapy-free option for patients with advanced EGFR-mutant NSCLC with acquired resistance to a third-generation EGFR TKI. // The Lancet Respiratory Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S2213260026002304?dgcid=rss_sd_all
Amivantamab, lazertinib, and bevacizumab: a chemotherapy-free option for patients with advanced EGFR-mutant NSCLC with acquired resistance to a third-generation EGFR TKI. The Lancet Respiratory Medicine. https://www.sciencedirect.com/science/article/pii/S2213260026002304?dgcid=rss_sd_all
“Amivantamab, lazertinib, and bevacizumab: a chemotherapy-free option for patients with advanced EGFR-mutant NSCLC with acquired resistance to a third-generation EGFR TKI.” The Lancet Respiratory Medicine.
@article{article32741,
title = {Amivantamab, lazertinib, and bevacizumab: a chemotherapy-free option for patients with advanced EGFR-mutant NSCLC with acquired resistance to a third-generation EGFR TKI},
journal = {The Lancet Respiratory Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S2213260026002304?dgcid=rss_sd_all}
}